GENPREX (GNPX)
(Delayed Data from NSDQ)
$1.41 USD
-0.06 (-4.08%)
Updated Aug 6, 2024 03:16 PM ET
After-Market: $1.43 +0.02 (1.42%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth B Momentum D VGM
Brokerage Reports
0 items in cart
GENPREX [GNPX]
Reports for Purchase
Showing records 1 - 20 ( 41 total )
Company: GENPREX
Industry: Medical - Biomedical and Genetics
Company: GENPREX
Industry: Medical - Biomedical and Genetics
Acclaim-3 Trial in Small Cell Lung Cancer Starts Patient Dosing; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: GENPREX
Industry: Medical - Biomedical and Genetics
Reqorsa and NPRL2 Gene Therapy Positive Preclinical Data; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: GENPREX
Industry: Medical - Biomedical and Genetics
Clinical Sites for Acclaim-3 SCLC Study Expanded; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: GENPREX
Industry: Medical - Biomedical and Genetics
Preclinical Data of NPRL2 Gene Therapy Published; 2023 Results; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: GENPREX
Industry: Medical - Biomedical and Genetics
Company: GENPREX
Industry: Medical - Biomedical and Genetics
Improving Survival in Lung Cancer; Initiating Coverage at Buy and $10 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: GENPREX
Industry: Medical - Biomedical and Genetics
Neutral Rated 1:40 Reverse Split, Market Cap Now $10M, Is a Raise Next?
Provider: Dawson James Securities, Inc.
Analyst: KOLBERT J
Company: GENPREX
Industry: Medical - Biomedical and Genetics
Neutral Rated Business Update but - Fails to Mention Reverse Split ATM
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: GENPREX
Industry: Medical - Biomedical and Genetics
Neutral Rated A Reverse Split and an ATM? Makes No Cents
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: GENPREX
Industry: Medical - Biomedical and Genetics
Is an ATM the Answer? Drip, Drip, Drip In the Prior Quarter (3Q) the Company Spent $7.7M with $11.7M Remaining So They Have to Do Something
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: GENPREX
Industry: Medical - Biomedical and Genetics
Neutral Rated Reports 3rd Quarter - Spends $7.7M, $11.7M Remains
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: GENPREX
Industry: Medical - Biomedical and Genetics
Neutral Rated Genprex to present data on the use of REQORSA
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: GENPREX
Industry: Medical - Biomedical and Genetics
Lowering to Neutral Reports Second Quarter Results: Spent $8M, $10M in Cash, raises $7.5M, but is it Enough?
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: GENPREX
Industry: Medical - Biomedical and Genetics
Genprex signs exclusive license agreement for additional diabetes technology-BUY Rated, $3.0 PT
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: GENPREX
Industry: Medical - Biomedical and Genetics
The patent covers the use of Genprex''s lead drug candidate, REQORSA Immunogene Therapy, in combination with PD1 antibodies through 2037.
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: GENPREX
Industry: Medical - Biomedical and Genetics
The company has developed a gene therapy that is designed to transform alpha cells in the pancreas into functional beta-like cells.
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: GENPREX
Industry: Medical - Biomedical and Genetics
Company: GENPREX
Industry: Medical - Biomedical and Genetics
Company: GENPREX
Industry: Medical - Biomedical and Genetics
Buy Rated The Diabetes Abstract is Out - Works in Non-Human Primates
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J